Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare Nautilus Biotechnology to similar businesses based on the strength of its earnings, institutional ownership, valuation, analyst recommendations, dividends, profitability and risk. Institutional & Insider Ownership […]